View Filing Data

Document and Entity Information - shares	6 Months Ended
Jun. 30, 2012	Jul. 30, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Trading Symbol	PLX
Entity Registrant Name	PROTALIX BIOTHERAPEUTICS, INC.
Entity Central Index Key	0001006281
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		91,923,406

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
CURRENT ASSETS:
Cash and cash equivalents	$ 59,280	$ 27,001
Accounts receivable:
Trade	1,536	1,374
Other	4,045	3,837
Inventories	1,029	279
Total current assets	65,890	32,491
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	1,072	1,043
PROPERTY AND EQUIPMENT, NET	17,342	18,271
Total assets	84,304	51,805
Accounts payable and accruals:
Trade	4,512	5,032
Other	11,962	7,540
Deferred revenues	4,858	6,121
Total current liabilities	21,332	18,693
LONG TERM LIABILITIES:
Deferred revenues	48,640	50,923
Long term liability	4,680	6,566
Liability for employee rights upon retirement	1,789	1,700
Total long term liabilities	55,109	59,189
Total liabilities	76,441	77,882
COMMITMENTS
SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)	7,863	(26,077)
Total liabilities and shareholders' equity (net of capital deficiency)	$ 84,304	$ 51,805

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

REVENUES

$ 26,113

$ 764

$ 29,974

$ 4,892

COMPANY'S SHARE IN COLLABORATION AGREEMENT

(855)

(5,382)

(988)

(3,510)

COST OF REVENUES

(3,279)

(132)

(4,599)

(910)

GROSS PROFIT (LOSS)

21,979

(4,750)

24,387

472

RESEARCH AND DEVELOPMENT EXPENSES

^[1]

(10,544)

(8,768)

(19,391)

(19,331)

less - grants and reimbursements

1,689

1,449

3,692

3,741

RESEARCH AND DEVELOPMENT EXPENSES, NET

(8,855)

(7,319)

(15,699)

(15,590)

GENERAL AND ADMINISTRATIVE EXPENSES

^[2]

(3,504)

(1,799)

(5,133)

(3,788)

OPERATING Profit (LOSS)

9,620

(13,868)

3,555

(18,906)

FINANCIAL INCOME - NET

179

183

165

NET PROFIT (LOSS) FOR THE PERIOD

$ 9,642

$ (13,689)

$ 3,738

$ (18,741)

EARNINGS (LOSS) PER SHARE OF COMMON STOCK:

BASIC

$ 0.11

$ (0.16)

$ 0.04

$ (0.22)

DILUTED

$ 0.10

$ (0.16)

$ 0.04

$ (0.22)

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE:

BASIC

91,526,224

85,579,534

89,702,496

83,686,094

DILUTED

94,881,167

85,579,534

92,670,033

83,686,094

[1]	Includes share-based compensation 2,445 256 2,384 152
[2]	Includes share-based compensation 1,314 265 1,246 127

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Common Stock

Additional paid-in capital

Accumulated deficit

Beginning Balance (in shares) at Dec. 31, 2010

^[1]

81,248,472

Beginning Balance at Dec. 31, 2010

$ (11,323)

$ 81

$ 124,044

$ (135,448)

Common stock issued for cash (net of issuance costs) (in shares)

^[1]

4,000,000

Common stock issued for cash (net of issuance costs)

20,590

$ 4

20,586

Share-based compensation

521

Exercise of options granted to employees and non-employees (in shares)

^[1]

333,272

Exercise of options granted to employees and non-employees

250

$ 1

249

Net Profit (loss) for the period

(18,741)

Ending Balance (in shares) at Jun. 30, 2011

^[1]

85,581,744

Ending Balance at Jun. 30, 2011

(8,703)

$ 86

145,400

(154,189)

Beginning Balance (in shares) at Dec. 31, 2011

^[1]

85,630,157

Beginning Balance at Dec. 31, 2011

(26,077)

$ 86

145,814

(171,977)

Common stock issued for cash (net of issuance costs) (in shares)

^[1]

5,175,000

Common stock issued for cash (net of issuance costs)

25,388

$ 5

25,383

Share-based compensation

3,759

Exercise of options granted to employees and non-employees (in shares)

^[1]

1,117,249

Exercise of options granted to employees and non-employees

1,055

$ 1

1,054

Net Profit (loss) for the period

3,738

Ending Balance (in shares) at Jun. 30, 2012

^[1]

91,922,406

Ending Balance at Jun. 30, 2012

$ 7,863

$ 92

$ 176,010

$ (168,239)

[1]	Common Stock, $0.001 par value; Authorized - as of June 30, 2012 and June 30, 2011 - 150,000,000 shares.

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A91
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 39
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net profit (loss)	$ 3,738	$ (18,741)
Adjustments required to reconcile net profit (loss) to net cash provided by (used in) operating activities
Share based compensation	3,759	521
Depreciation and write down of fixed assets	1,860	1,801
Financial income, net (mainly exchange differences)	(3)	(73)
Changes in accrued liability for employee rights upon retirement	133	77
Gain on amounts funded in respect of employee rights upon retirement	(14)	(16)
Changes in operating assets and liabilities:
Increase (decrease) in deferred revenues (including non-current portion)	(3,546)	149
Decrease (increase) in accounts receivable	(462)	2,049
Decrease (increase) in inventories	(750)	652
Increase in accounts payable and accruals (including long term)	2,128	4,770
Net cash provided by (used in) operating activities	6,843	(8,811)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,047)	(4,016)
Amounts funded in respect of employee rights upon retirement, net	(44)	(77)
Net cash used in investing activities	(1,091)	(4,093)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of shares, net of issuance cost	25,478	20,650
Exercise of options	1,086	259
Net cash provided by financing activities	26,564	20,909
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(37)	149
NET INCREASE IN CASH AND CASH EQUIVALENTS	32,279	8,154
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	27,001	35,900
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	59,280	44,054
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Purchase of property and equipment	1,357	1,995
Issuance cost not yet paid and accruals - other	$ 150	$ 60

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2012

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

General

Operation

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company’s proprietary ProCellEx^® protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company’s two subsidiaries are referred to collectively herein as the "Subsidiaries."

On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company’s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa is the first FDA-approved plant cell-based recombinant therapeutic protein.

Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO™ by Pfizer Inc. ("Pfizer"), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States, which are recorded as revenues during the current period. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.

The Company is cooperating with Pfizer to obtain marketing approval for taligulcerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for the European Union, Israel, Brazil and Australia. In June 2012, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted an opinion recommending against the marketing authorization of taliglucerase alfa in the European Union. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV^®, Shire plc's Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa. The Company and Pfizer are currently working together, along with other interested parties, to determine the next steps regarding the CHMP opinion.

In addition to taliglucerase alfa, the Company is developing certain other products using ProCellEx.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and, both within and outside of the United States, through the Company's clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. In July 2009, following a request by the FDA, the Company submitted a treatment protocol to the FDA in order to address an expected shortage of the current enzyme replacement therapy approved for Gaucher disease. The treatment protocol was approved by the FDA in August 2009, and the Company is continuing to treat patients in the United States under this protocol as it winds down with patients being moved to commercial treatment with Elelyso. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.

On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.

Liquidity and Financial Resources

In addition to the FDA approval, successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. In addition, the Company is eligible to receive potential milestone payments equal to $25.0 million, in the aggregate, for matters relating to the successful achievement of regulatory approval of taliglucerase alfa in the European Union. Notwithstanding the FDA's approval of taliglucerase alfa, there can be no assurance that the Company will receive regulatory approval of taliglucerase alfa in the European Union or any other jurisdiction, nor is there any assurance that the Company will receive regulatory approval of any of its other product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.

Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.

Earnings (loss) per share

Basic earnings (loss) per share are calculated by dividing the net profit (loss) by the weighted average number of shares of the Company's common stock, par value $0.001 (the "Common Stock"), outstanding during each period.

Diluted earnings per share are calculated by dividing the net profit by the weighted-average number of shares of common stock outstanding during each period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive shares had been issued. Potentially dilutive shares include outstanding stock options granted to employees and non-employees.

The weighted average number of shares outstanding used to calculate earnings (loss) per share were as follows:

	Six Months Ended				Three Months Ended
	June 30, 2012		June 30, 2011		June 30, 2012		June 30, 2011
Weighted average common shares outstanding for basic calculation		89,702,496		83,686,094		91,526,224		85,579,534
Weighted average dilutive effect of stock options		2,967,537		-		3,354,943		-
Weighted average common shares outstanding for diluted calculation		92,670,033		83,686,094		94,881,167		85,579,534

Diluted earnings (loss) per share do not include options of the Company in the amount of 7,537,094 and 1,785,542 shares of Common Stock for the six months ended June 30, 2011 and 2012, respectively, and 7,435,271 and 1,785,542 shares of Common Stock for the three months ended June 30, 2011 and 2012, respectively, because the effect would be anti-dilutive.

STOCK TRANSACTIONS

6 Months Ended

Jun. 30, 2012

STOCK TRANSACTIONS

NOTE 3 - STOCK TRANSACTIONS

On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25,388,000 (net of underwriting commissions and issuance costs of approximately $1,780,000).

During the six months ended June 30, 2012, the Company issued a total of 1,117,249 shares of Common Stock in connection with the exercise of a total of 1,117,249 options by certain officers and employees of the Company. The Company received aggregate cash proceeds equal to approximately $1,055,000 in connection with such exercises.

Following FDA approval of taliglucerase alfa on May 1, 2012, the Company started recognizing compensation costs in relation to performance-based awards that were granted in February 2010 to certain officers and employees of the Company which vest over a three-year period commencing upon the FDA's approval of taliglucerase alfa. During the second quarter of 2012, the Company recorded an expense in the amount of approximately $3.5 million for the cumulative period from the date of grant.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2012

General

General

Operation

In addition to taliglucerase alfa, the Company is developing certain other products using ProCellEx.

Liquidity and Financial Resources

Basis of Presentation

Basis of Presentation

Net loss per share

Earnings (loss) per share

The weighted average number of shares outstanding used to calculate earnings (loss) per share were as follows:

	Six Months Ended				Three Months Ended
	June 30, 2012		June 30, 2011		June 30, 2012		June 30, 2011
Weighted average common shares outstanding for basic calculation		89,702,496		83,686,094		91,526,224		85,579,534
Weighted average dilutive effect of stock options		2,967,537		-		3,354,943		-
Weighted average common shares outstanding for diluted calculation		92,670,033		83,686,094		94,881,167		85,579,534

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References + Details

Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended		31 Months Ended
	Jun. 30, 2012 $ / shares shares	Jun. 30, 2011 $ / shares shares	Jun. 30, 2012 USD ($) Entity $ / shares shares	Jun. 30, 2011 $ / shares shares	Jun. 30, 2012 USD ($) $ / shares
Significant Accounting Policies [Line Items]
Number of Subsidiaries \| Entity			2
Pfizer Agreement, upfront payment received					$ 60.0
Common stock, par value per share \| $ / shares	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Protalix Bio Therapeutics Incorporation
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	40.00%		40.00%		40.00%
Pfizer Incorporation
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	60.00%		60.00%		60.00%
Stock Options
Significant Accounting Policies [Line Items]
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive \| shares	1,785,542	7,435,271	1,785,542	7,537,094
Upon Filing of Pediatric Investigation Plan to EMA
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received			$ 5.0
Upon each FDA and European Medicine Agency approval
Significant Accounting Policies [Line Items]
Milestone payment triggered			$ 25.0

Stock Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Feb. 29, 2012	Jun. 30, 2012	Jun. 30, 2012	Jun. 30, 2011	Feb. 22, 2012
Class of Stock [Line Items]
Underwritten public offering, common stock issued and sold					5,175,000
Underwritten public offering, common stock price per share					$ 5.25
Underwritten public offering, net proceeds from issuance	$ 25,388,000
Underwritten public offering, commissions and issuance costs	$ 1,780,000
Cash proceeds from exercise of options			$ 1,086,000	$ 259,000
Performance-based awards, recorded expense			$ 3,759,000	$ 521,000
Performance-based awards
Class of Stock [Line Items]
Performance-based awards, vesting period		3 years
Performance-based awards, recorded expense		$ 3,500,000
Certain employees and non-employees
Class of Stock [Line Items]
Common Stock issued in connection with exercise of options			1,117,249
Cash proceeds from exercise of options			$ 1,055,000

Subsequent Events - Additional Information (Detail)	1 Months Ended	6 Months Ended
Subsequent Events - Additional Information (Detail)	Jul. 31, 2012 USD ($) Installment Month shares	Jun. 30, 2012 USD ($)	Jun. 30, 2011 USD ($)	Jul. 16, 2012 USD ($) shares
Subsequent Event [Line Items]
Cash proceeds from exercise of options \| $		$ 1,086,000	$ 259,000
Stock Compensation Plan \| Restricted Stock
Subsequent Event [Line Items]
Fair value of common stock at grant date \| $				$ 8,580,000
Stock Compensation Plan \| Restricted Stock \| Executive Officer
Subsequent Event [Line Items]
Shares of common stock approved for grant				1,500,000
Shares of common stock issued	1,100,000
Number of installments for vesting of stock \| Installment	16
Shares of common stock issued, vesting period	4 years
Shares of common stock issued, lock up period \| Month	24
Stock Compensation Plan \| Restricted Stock \| Employees
Subsequent Event [Line Items]
Shares of common stock issued	400,000
Number of installments for vesting of stock \| Installment	12
Shares of common stock issued, vesting period	3 years
Option Exercise \| Certain employees
Subsequent Event [Line Items]
Common Stock issued in connection with exercise of options	1,000
Cash proceeds from exercise of options \| $	$ 120

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Research and Development Expense
Share-based compensation	$ 2,384	$ 152	$ 2,445	$ 256
General and Administrative Expense
Share-based compensation	$ 1,246	$ 127	$ 1,314	$ 265

Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Schedule of Inventory [Line Items]
Raw materials	$ 731	$ 279
Work in progress	89
Finished goods	209
Total inventory	$ 1,029	$ 279

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Common stock issued for cash, issuance costs	$ 1,780	$ 1,410
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, Authorized	150,000,000	150,000,000